Assessment of copeptin, ghrelin and pro BNP in metabolic syndrome

Basit Öğe Kaydı
dc.contributor.authorEmre, A.
dc.contributor.authorSibel, K.
dc.contributor.authorBurcu, B.
dc.contributor.authorGulcin, A. A.
dc.contributor.authorAlpaslan, K.
dc.contributor.authorCumhur, B.
dc.date.accessioned2021-11-01T15:03:14Z
dc.date.available2021-11-01T15:03:14Z
dc.date.issued2020
dc.department[Belirlenecek]
dc.description.abstractThis study was aimed to assessment the relationship between MetS and three different biomarkers (Copeptin, Ghrelin and NT-proBNP) that related to metabolism and cardiovascular system. Metabolic syndrome (MetS) is a multifactorial disorder with metabolic abnormalities including central obesity, insulin resistance, atherogenic dyslipidemia, and hypertension that increase the risk of the development of diabetes and cardiovascular disease (CVD) at highly rates. Methods: Our study was evaluated according to the metabolic syndrome diagnostic criteria of the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHL-BI) and the International Diabetes Federation (IDF). A total of seventy four subjects (44-MetS and 30-healthy) included in this study. Copeptin and ghrelin were determined using the ELISA. The amino-terminal pro-brain natriuretic peptide (NT-proBNP) was measured through chemiluminescence method. The biochemical parameters including blood glucose-insulin values, lipid profiles were also measured. Results: Total cholesterol, fasting blood glucose, insulin, LDL were significantly higher in the MetS than healthy and HDL was significantly lower. There was no significant difference between thyroid tests. Copeptin was significantly higher in MetS than healthy (p=0.007). Ghrelin was lower in MetS than in the healthy (p=0.002). ProBNP was higher in Mets compared to the control (p=0.028). Conclusion: Copeptin, Ghrelin and ProBNP are directly related not only in itself but also to various metabolic syndrome components. With the data obtained in our study, it is thought to be a guide in follow-up of high risk patients.
dc.identifier.issn2042-8545
dc.identifier.issn2053-4787
dc.identifier.issue1en_US
dc.identifier.urihttps://hdl.handle.net/11491/7034
dc.identifier.volume28en_US
dc.identifier.wosWOS:000592496800001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherFsg Communications Ltd
dc.relation.ispartofAfrican Journal Of Diabetes Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCopeptinen_US
dc.subjectGhrelinen_US
dc.subjectMetabolic syndromeen_US
dc.subjectProBNP gluconeogenesisen_US
dc.subjectGlycogenolysisen_US
dc.titleAssessment of copeptin, ghrelin and pro BNP in metabolic syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu